Molecular Biology and Genetics of Amyotrophic Lateral Sclerosis Michael Sidel February 13, 2008.

Slides:



Advertisements
Similar presentations
Sporadic AD familial AD etiology environmental factors, genetic predisposition etiology oligomerization of A 42 and initial (diffuse) A 42 deposits subtle.
Advertisements

ALS Research Yesterday, Today and Tomorrow Heather D. Durham, PhD.
ALS Research Update 2008 Richard A. Lewis MD Director, Hiller ALS Clinic and Research Center Wayne State University School of Medicine Detroit, Michigan.
The genetics of mitochondrial disease
Genetic Modified Cell Therapy for Amyotrophic Lateral Sclerosis (ALS) Tianyi Cai PBIO /02/2014.
ALS By Arjun Puri and Navdeep Saini. Intro Amyotrophic Lateral Sclerosis Neurodegenerative disease Incurable and fatal Can affect anyone Life expectancy.
Apoptosis By Dr Abiodun Mark .A.
Comparing the Toxicity of Zinc Deficient Superoxide Dismutase (SOD) and the Quad SOD mutant: Implications for Amyotrophic Lateral Sclerosis Jesse Fitzpatrick.
Chapter 18 Human Heredity by Michael Cummings ©2006 Brooks/Cole-Thomson Learning Chapter 18 Genetics of Behavior.
An Investigation of the Interactions Between Zinc-deficient and Copper, Zinc Superoxide Dismutase Katie Meyers Dr. Joe Beckman Department of Biochemistry/Biophysics.
Investigation of mutated Cu/Zn Superoxide Dismutase Sam Schuberg Beckman Laboratory Howard Hughes Medical Institute: Summer 2007.
Natalie Biggs Mentor: Dr. Joseph Beckman
Parkinson’s Disease Pathology 430/826 The Molecular Basis of Disease Neurological Genetics 9 th March 2015 Dr. John Rossiter
Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig’s disease)
Cellular Degeneration and Ageing Susan Rutherford and Sarah Christie.
Chapter 21. Molecular Mechanisms of Neurological Disease Copyright © 2014 Elsevier Inc. All rights reserved.
Multiple Sclerosis Rohith M. Reddy. Multiple sclerosis (MS) involves an immune-mediated process in which an abnormal response of the body’s immune system.
Amyotrophic lateral sclerosis (ALS). What is amyotrophic lateral sclerosis? It is a progressive neurological disease that affects the control of muscle.
By Intracerebroventricular Delivery of VEGF in a Rat Model of ALSEGF in a Rat Model of ALS Treatment of Motoneuron Degeneration.
Amyotrophic Lateral Sclerosis
Diseases that Result from Abnormal Mitochondrial Function Lu Qiping April 15, 2011.
Toll-Like Receptors in CNS Viral Infections Unclear role of TLRs in natural infections TLR3, -7, -8, -9 recognize viral nucleic acids. Localized intracellularly.
ATAXIA TALANGIECTASIA
LOU GEHRIG’S DISEASE.  Also known as Amyotrophic Lateral Sclerosis  Is a disease of the nerve cells in the brain and spinal cord that control voluntary.
Parkinson’s Disease superKAT :).
CHAPTER 23: Neurological Disorders in Women. Introduction Gender differences exist in the development and expression of several neurological disorders,
Introduction Alzheimer’s disease (AD) is a neurodegenerative disease associated with brain shrinkage and the loss of neurons, particularly cholinergic.
PATHOLOGIC AGGREGATION OF THE BRAIN PROTEIN  -SYNUCLEIN CAUSES CELL DEATH IN PARKINSON AND ALZHEIMER DISEASE, Wenbo Zhou, PhD and Curt R. Freed, MD Division.
Programmed Cell Death. Why do some cells need to die? To accomplish morphogenetic ends, eg. Separation of fingers during embryogenesis of the hand To.
Pathogenesis of Cerebral Infarction at Cellular & Molecular Levels By: Reem M Sallam, MD, PhD.
Aging and Reactive oxygen Species. Aging: What is it?  Aging, has been termed generally as a progressive decline in the ability of a physiological process.
漸凍症 amyotrophic lateral sclerosis. Lou Gehrig's disease 1939 Jean-Martin Charcot Amyotrophic lateral sclerosis (ALS) (Rosen DR et al. Nature 1993) 1869.
Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig’s disease)
Haythum O Tayeb R3, Neurology.  Brief review of the genetics and molecular biology of CMT & HNPP with clinical correlation.
 Definition ◦ It is combination of two Latin words ◦ Pathos meaning disease ◦ Logos meaning study Pathology is a branch of medicine that deals with the.
Amyotrophic Lateral Sclerosis (ALS)
Cell Aging. Aging is generally characterized by the declining ability to respond to stress, increasing homeostatic imbalance and increased risk of aging-associated.
Under the supervision of miklós jászberényi
Α-synuclein transgenic mouse models of Parkinson’s disease Michelle Maurer December 2015.
Amyotrophic Lateral Sclerosis
Motor neuron disease.
N deg - 1 Characteristics of neurons u Cytoskeletal organization u Microtubules and motors u Neuronal intermediate filaments u Neurofilaments u Peripherin,
Pathogenesis and pathology of parkinsonism
Presented by: Vidyaningtyas BA, MD Yanuarita T, MD Widagdo S, MD.
The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice 한양대학교 대학원 신경과전공 박사과정 이상목 가족성 근위축성측삭경화증 모델 동물의 질병경과 완화를 보인 epigallocatechin.
ZOO405 by Rania Baleela is licensed under a Creative Commons Attribution- NonCommercial-ShareAlike 3.0 Unported LicenseRania BaleelaCreative Commons Attribution-
Alzheimer Disease (Senile Dementia) Characterized by progressive memory loss, is increasingly common in developed countries as populations include more.
Sapana Shinde, Aaron Ripley, Dr. Sok Kean Khoo MicroRNA expression studies in rotenone- induced cellular model for Parkinson’s disease Department of Cell.
Mouse Double Minute 2 (MDM2)
A potential therapy for ALS
III. Parkinson Disease.
Alpha-synuclein in Parkinson's disease
Parkinson’s Diseased Proteins in Relation to Autophagy
Nat. Rev. Neurol. doi: /nrneurol
Figure 2 ER stress and proteostasis in neurodegenerative diseases
ALS disease pathology and proposed disease mechanisms.
Measurement of Protein Aggregation Levels in Mutant scs2 Gene of Yeast to Determine whether the Ubiquitination Proteasome System of the Unfolded Protein.
Figure 3 VEGF in neurodegenerative disease
Parkinson's Disease Neuron
Autophagy in the Pathogenesis of Disease
Selective Neuronal Vulnerability in Neurodegenerative Diseases: from Stressor Thresholds to Degeneration  Smita Saxena, Pico Caroni  Neuron  Volume 71,
Traumatic Axonal Injury: Mechanisms and Translational Opportunities
Mechanisms Underlying Inflammation in Neurodegeneration
The Ubiquitin Proteasome System in Neurodegenerative Diseases
Volume 18, Issue 2, Pages (February 1997)
Nuclear factor erythroid 2-related factor 2 come modulatore genico di risposta allo stress ossidativo in pazienti affetti da Sclerosi Laterale Amiotrofica.
NERV222 Lecture 3 BIOCHEMISTRY NEUROPSYCHIATRY BLOCK
Early Onset of Severe Familial Amyotrophic Lateral Sclerosis with a SOD-1 Mutation: Potential Impact of CNTF as a Candidate Modifier Gene  Ralf Giess,
LHON/LHON plus Andrea Gropman, M.D., FAAP, FACMG, FANA
UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration
Presentation transcript:

Molecular Biology and Genetics of Amyotrophic Lateral Sclerosis Michael Sidel February 13, 2008

Goals To have a basis for the understanding of the genetics involved in ALS To understand the current theories and concepts that underlie the pathogenesis of ALS

Outline Brief clinical overview of the disease –1 slide The genetics of ALS –6 Slides The pathology of ALS –5 Slides An understanding of the disease pathogenesis –Priceless (or 8 slides)

Some Clinical Factoids about ALS A progressive neurodegenerative disease Involvement of motor neurons at all levels 50% mortality at 3 years Several clinically related variants: –Primary lateral sclerosis –Primary muscular atrophy –Progressive bulbar palsy 90% of the cases are considered “sporadic” 10% of cases are considered familial

Some of the Genetics of ALS

Genetics of ALS 10% of cases of ALS have history of first- degree relative with the disease –Suggests Autosomal Dominant inheritance Research direction: –Isolating genes involved in clear familial disease –Isolating polymorphisms that are potentially risk factors in sporadic disease

Genetics of Familial ALS Mitchell and Borasio, Lancet2007; 369: 2031–41

Genetics of Familial ALS Mitchell and Borasio, Lancet2007; 369: 2031–41

Genetics of Familial ALS Mitchell and Borasio, Lancet2007; 369: 2031–41

Genetics of Familial ALS Mitchell and Borasio, Lancet2007; 369: 2031–41

Genetics of Familial ALS Represents 10-20% of cases of familial ALS Over 100 mutations to the gene are related to pathology Gain of function mutation causes the disease pathology –From mouse model data

Genetics of Familial ALS Mitchell and Borasio, Lancet2007; 369: 2031–41

Genetics of Familial ALS Mitchell and Borasio, Lancet2007; 369: 2031–41

Genetics Associations in ALS There are other genetic mutations that may alter the risk of developing ALS: Examples: –Angiogenin (14q11.2) –Vascular endothelial growth factor (6p12) –Survival motor neuron (5q12.2-q13.3) –Neurofilament protein (22q12.2) –Multivesicular body protein 2B (2p11.2)

PATHOLOGY OF ALS

Gross Pathology Motor neuron degeneration and death with gliosis Gliosis of the CST Atrophy of ventral nerve roots

Microscopic Pathology Intracellular inclusions -Bunina bodies -Ubiquinated inclusions (not tau)

PATHOGENIC MECHANISMS OF ALS

Proposed Pathogenic Mechanisms in ALS Oxidative Stress Excitotoxicity Abnormal Protein Precipitation and/or Aggregation Cytoskeletal defects Axonal transport Neuroinflammation Abnormalities in hypoxia-regulated genes Apoptosis

Oxidative Stress Motor neuron damage as a result of oxidative stress Not necessarily linked to gene mutation –i.e. SOD1 Post-mortem studies have shown evidence of increased oxidative by- products Linked to other mechanisms

Excitotoxicity Glutamate mediated Possible mechanisms of disease include: –Production of free radicals –Increased intracellular calcium Decreased EAAT2 functions has been described in some ALS post-mortem studies

More on Excitoxocity Goodall and Morrison Expert Reviews in Molecular Medicine. Vol. 8(11) 24 May 2006.

Abnormal Protein Precipitation and/or Aggregation Abnormal protein aggregates, including Bunina bodies, ubiquitinated inclusions and neurofilament rich hyaline inclusions are pathological hallmarks of ALS Unknown cause and effect relationship SOD1 mutants can misfold and coprecipitate with other molecules as well

Cytoskeletal Defects Neurofilament proteins are the most abundant structural protein in motor neurons, and aggregates of neurofilament proteins motor neurons are commonly seen in ALS Can be found as part of inclusions Overexpression of peripherin or alpha- internexin in mice can cause motor neuron disease

Axonal Transport Axonal transport of materials is essential for neuronal function and survival Dynactin is a protein involved in fast retrograde transport in the axon Mutations in this gene have been associated with motor neuron disease

Neuroinflammation Microglia have been found to be activated in parts of CNS affected by ALS COX-2 Receptors and downstream prostaglandins are elevated in ALS brains

Apoptosis Represents eneergy-dependent programmed cell death In human ALS spinal cord tissue, increases in caspase-1 and -9 activation have been detected Very unclear how much this plays a role in the pathogenesis of the disease

Goodall and Morrison. Expert Reviews in Molecular Medicine. Vol. 8(11) 24 May 2006.

Why Motor Neurons? Extreme size of cells High metabolic activity Sensitivity to mitochondrial dysfunction Elevated neurofilament content Reduced capacity to buffer calcium

Conclusions We do not understand ALS Familial ALS is caused by genetic mutations and is rare Sporadic ALS is caused by a combination of: –Genetic susceptibility –Environmental triggers –Motor neuron specific cellular damage

Key Points to Remember 1.Main cause of familial ALS is SOD1 mutations with are gain of function 2.Bunina bodies are inclusions found in ALS motor neurons 3.Excitoxicity and oxidative damage are likely major contributors to motor neuron death in ALS

References Valdmanis, P.N. and Rouleau, G.A. Genetics of familial amyotrophic lateral sclerosis. Neurology. 2008;70: Goodall, E.F. and Morrison, K.E. Amyotrophic lateral sclerosis: proposed mechanisms and pathways to treatment. Expert Reviews in Molecular Medicine. Vol. 8; Issue 11; 24 May Mitchell, J.D. and Barasio, G.D. Amyoptrophic Lateral Sclerosis. Lancet 2007; 369: